Research released at the ASCO meeting in Chicago confirms that regular exercise is a must for men with advanced prostate cancer. It was found that a regular and structured physical exercise program reduces cytokine production which is related to depression and to the inflammatory processes. According to the researchers these factors may impact prostate cancer [...]
In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared [...]
Current practice has been to immediately begin hormone therapy (ADT) as soon as a man has a bio-chemical (PSA only) relapse. A recent presentation at ASCO 2014 has shown that immediate ADT actually offers little or no survival benefit over deferred ADT to advanced prostate cancer survivors who experience a PSA only relapse after radical [...]
I was asked if there was one item that was a real game changer at the American Society of Clinical Oncologists (ASCO) meeting for men with advanced prostate cancer. The answer is yes, at this meeting it was formally shown by a study that starting chemotherapy (docetaxel) along with androgen deprivation therapy (ADT) in some [...]
I have been at American Association of Clinical Oncologists (ASCO) since last Thursday. On the prostate cancer front the most exciting part of the meeting has been our being in Chicago and that the weather which has been fantastic. The only truly newsworthy thing that I have come across so far has been an abstract [...]